FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16% in 2011 to almost 11% in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniques to address the understanding around targets and leads are inefficient. The increasing volume and veracity of clinical and research data compels traditional providers to leverage converging technologies such as artificial intelligence (AI), machine learning, natural language processing, and advanced analytics to shift from static to dynamic and adaptive data management practices. The ecosystem for supporting this growth has matured: several technology start-ups and large commercial vendors have already started delivering the impact through their products and solutions catering to drug discovery. While the benefits over the next 2 to 3 years are expected to be achieved through improved drug pipelines and faster clinical approval of new molecules, beyond that companies that integrate AI solutions will see significant impact on efficiency, cost savings and commercial success depending on their business goals.

Frost & Sullivan analysis shows that the AI impact over the pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of the industry revenue, amounting to more than $50 billion in potential annual impact. This Frost Radar™ recognizes the participants that are at the forefront of developing and employing the tools. This is an industry-first benchmarking study that provides an introduction to the ecosystem and recognizes the pioneering companies.

The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients.


  • STRATEGIC IMPERATIVE AND GROWTH ENVIRONMENT
    • STRATEGIC IMPERATIVE
    • AI FOR DRUG DISCOVERY MARKET SEGMENTATION
    • GROWTH ENVIRONMENT
  • FROST RADARTM
    • AI FOR DRUG DISCOVERY IN THE PHARMACEUTICAL INDUSTRY
    • COMPETITIVE ENVIRONMENT
  • COMPANIES TO ACTION
    • ACURASTEM, INC.
    • AI THERAPEUTICS
    • ATOMWISE
    • BenevolentAI
    • BERG
    • BIOVISTA INC.
    • COTINGA PHARMACEUTICALS INC.
    • EVAXION BIOTECH
    • EXSCIENTIA LTD.
    • GRITSTONE ONCOLOGY, INC.
    • HEALX
    • INSILICO MEDICINE
    • LANTERN PHARMA, INC.
    • PHARNEXT
    • RECURSION PHARMACEUTICALS
    • twoXAR
  • STRATEGIC INSIGHTS
  • NEXT STEPS: LEVERAGING THE FROST RADAR TM TO EMPOWER KEY STAKEHOLDERS
    • SIGNIFICANCE OF BEING ON THE FROST RADAR TM
    • FROST RADAR TM EMPOWERS THE CEO'S GROWTH TEAM
    • FROST RADAR TM EMPOWERS INVESTORS
    • FROST RADAR TM EMPOWERS CUSTOMERS
    • FROST RADAR TM EMPOWERS THE BOARD OF DIRECTORS
  • FROST RADAR TM ANALYTICS
    • FROST RADAR TM: BENCHMARKING FUTURE GROWTH POTENTIAL

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook